杠柳毒苷体外抑制肝癌细胞和乳腺癌细胞增殖的实验研究

目的探讨杠柳毒苷在体外对人乳腺癌MDA—MB．468细胞和人肝癌HepG2细胞增殖的影响。方法MTT法观察杠柳毒苷对人乳腺癌MDA-MB-468细胞和人肝癌HepG2细胞增殖的抑制作用，流式细胞术观察杠柳毒苷对两种肿瘤细胞的细胞增殖周期作用。结果与对照组比较，杠柳毒苷能明显抑制两种肿瘤细胞的增殖，其抑制率与药物浓度和作用时间呈正相关。流式细胞仪检测发现，杠柳毒苷对乳腺癌MDA-MB-468细胞和肝癌HepG2细胞持续作用24h后，可以使GdG1期细胞增多，G2／M期细胞减少。结论杠柳毒苷具有抑制乳腺癌MDA-MB-468细胞和肝癌HepG2细胞增殖的作用，并可将乳腺癌MDA-MB-468细胞和肝癌HepG2细胞的细胞生长周期阻滞在G0／G1期。

Inhibition of periplocin on human hepatoma carcinoma and breast carcinoma cells in vitro

Objective To discuss the effect of periplocin on the proliferation of the breast carcinoma MDA-MB-468 cells and hepatocellular carcinoma HepG2 cells in vitro. Methods MTT method was used to examine the proliferation of MDA-MB-468 and HepG2 cells, and flow cytometry was used to observe the effect of periplocin on cell cycle of the two kinds of tumer cells. Results Compared with the control group, periplocin could obviously inhibit the proliferation of two kinds of cells, and the inhibitory rate was positively correlated with drug level and action time. By flow cytometry, it was found that after 24 h treatment, periplocin induced cell cycle （G0/G1） arrest in MDA-MB-468 and HepG2 cells . Conclusion Periplocin could inhibit the proliferation of the breast carcinoma MDA-MB-468 and hepatocellular carcinoma HepG2 cells, and block their cell cycle in G0/G1 phase.